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ABSTRACT An enzyme has been partially purified from
canine and porcine cerebral cortical extracts that differs from
trypsin in that it manifests some degree of hormone specificity
since it converts porcine cholecystokinin to smaller immuno-
reactive forms, i.e., the COOH-terminal dodecapeptide and
octapeptide fragments, but fails to convert big gastrin (34 amino
acids) to heptadecapeptide gastrin. This enzyme is distin-
guishable from trypsin not only in substrate specificity, but also
in several physicochemical proprties. It is not inhibited in the
presence of concentrations of lima bean trypsin inhibitor suf-
ficient to inhibit 1 mg of trypsin r ml of incubation mixture.
It is inactivated when incubate with substrate at 450C for 1
hr., whereas trypsin remains fully active when incubated under
the same conditions at 550C. The enzyme elutes in the void
volume on Sephadex G-50 and G-75 gel filtration. On sucrose
gradient centrifugation, the proteolytic activity associated with
trypsin is recovered above a bumin but that of the solubilized
brain enzyme is recovered below gamma globulin. The enzyme
is not detectable in splenic extracts, which do contain nonspe-
cific proteases capabfe of completely degrading cholecystokinin.
Further investigation is required to determine whether the en-
zyme in the gut that converts cholecystokinin to the bioactive
and immunoactive COOH-terminal fragments resembles or is
different from the brain converting enzyme.
Over the past decade it has become evident that many, if not
all, peptide hormones are found in their tissues of origin in more
than one form (see ref. 1 for review). Following the discovery
that proinsulin is the precursor of insulin (2) it has generally
been assumed that, if the larger hormonal form contains a
peptide with amino acid sequence identical to or if it is con-
vertible by enzymatic conversion to a smaller, well-charac-
terized, and more biologically active form, the larger molecule
is a prohormone, whether or not the biosynthetic precursor
relationship has been established. Thus, a precursor relationship
has been definitely established for several peptide hormones,
including proinsulin (2) and proparathyroid hormone (3-5),
but it has only been assumed for others, such as big (34-
amino-acid) gastrin (gastrin-34) (6, 7) and the 39-amino-acid
cholecystokinin variant (CCK-39) (8). Similarly, cholecystokinin(CCK-33) can be considered to be a precursor for the chole-
cystokinin dodecapeptide (CCK-12) and octapeptide (CCK-8),
the COOH-terminal fragments which have biologic potencies
greater than that of the presumed parent CCK-33 molecule.
Although several groups have reported on the existence in
the tissues of origin of tryptic-like enzymes involved in the
conversion of proinsulin (9) and proparathyroid hormone (10,
11), precursors to insulin and parathyroid hormone, respec-
tively, no evidence has as yet been presented to determine
whether the same enzyme may be involved in processing more
than one hormonal family. In this report we characterize and
partially purify an enzyme, obtained from extracts of mam-
malian brain, which converts porcine cholecystokinin(pCCK-33) to smaller immunoreactive forms but which fails
to convert gastrin-34 to heptadecapeptide gastrin (gastrin-17).
We demonstrate that this enzyme is distinguishable from
trypsin in a variety of physicochemical systems.
MATERIALS AND METHODS
Preparation and Fractionation of Brain Extracts as Source
of Enzyme. Cold water extracts of porcine and canine cerebral
cortical tissues were prepared as follows. Animals were killed
by injection of lethal doses of sodium pentathol. Immediately
after injection the entire brain was removed, placed in a plastic
bag, and rapidly frozen on dry ice. Pieces of frozen cerebral
cortical tissue were subsequently cut and extracted at 40C with
a Teflon grinder in distilled water, which was added to a con-
centration of 0.1 g of wet weight tissue per ml. No differences
in activity were observed if the extractant was 0.9% NaCl or
0.25 M phosphate buffer (pH 7.5). The extracts were centri-
fuged at 10,000 X g for 15 min. The supernatants were tested
for ability to convert CCK-33 and gastrin-34 to smaller im-
munoreactive forms as described below. They were also chro-
matographed on 1 X 50 cm columns containing Sephadex G-50
or G-75. The columns were calibrated by application of ra-
dioactive markers to establish the positions of the void volume
and the radioiodide peak. After application of brain extract,
the columns were eluted with 0.9% NaCl and 1-ml fractions
were collected and tested for enzymatic activity.
The active fractions from the Sephadex column were also
centrifuged at 190,000 X g for 2 hr. Portions of the supernatant
and resuspended pellets were then layered above a continuous
10-40% sucrose gradient in a 5-ml polyethylene tube and
centrifuged at- 45,000 rpm for 22 hr in a Spinco model L ul-
tracentrifuge fitted with a Beckman swinging bucket rotor
(SW50. 1). After the centrifuge came to rest without braking,
successive 0.4-ml samples were removed from the bottom of
each tube and studied for enzyme activity. For comparison,
125I-labeled albumin, 125I-labeled gamma globulin, and pan-
creatic trypsin were similarly layered in duplicate tubes and
centrifuged along with the active fractions of the brain ex-
tracts.
Substrates and Enzymatic Assay. Two substrates were used:
purified pCCK-33, which was a gift from Victor Mutt (Gas-
trointestinal Hormone Research Unit, Stockholm) and was re-
ceived through the NIAMDD Gastrointestinal Hormone Re-
source, Bethesda, MD, and gastrin-34, which was a gift from
R. A. Gregory (University of Liverpool, England) and which
had been purified from a human gastrinoma.
Enzymatic activity was tested by incubating the brain extract
Abbreviations: CCK-33, the 33-amino-acid cholecystokinin; CCK-12,
COOH-terminal cholecystokinin dodecapeptide; CCK-8, COOH-
terminal cholecystokinin octapeptide; gastrin-34, the 34-amino-acid
big gastrin; gastrin-17, heptadecapeptide gastrin.
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or the various fractions from the separation systems with pCCK
or gastrin-34, usually at concentrations of 500 ng/ml in 0.25 M
phosphate buffer (pH 7.5), fortified with 1 mg of human serum
albumin per ml. The incubation was generally carried out at
250C for 60 min. At the end of that time the samples were
boiled for 5 min to inactivate the enzyme. The substrates, before
and after enzymatic digestion, were then fractionated by starch
gel electrophoresis or Sephadex gel filtration. Radioimmuno-
assay of the eluates was then used to determine alterations in
substrate induced by enzymatic conversion. The same substrates
were labeled with 125I and fractionated similarly as well as on
paper chromatoelectrophoresis, and the enzymatic degradation
of labeled and unlabeled substrates was compared.
The activity and specificity of the brain enzyme were com-
pared with those of chymotrypsin-free trypsin (Sigma, bovine
trypsin, DCC-treated type XI) at a concentration of 1 mg/ml.
The active fraction from the Sephadex purification of the brain
extract was used at a concentration of 40,gl of active fraction
per ml of incubation volume. The effect of temperature on
enzymatic activity was tested at 25°, 379, 450, and 55'C by
preincubating each of the enzymes for 15 min to bring it to
temperature, then adding each of the two 125I-labeled substrates
and incubating for 60 min longer at the four temperatures. The
pH range of activity of both enzymes was evaluated by incu-
bation of enzyme and substrate at pH 4.5-9. For some studies
excess lima bean trypsin inhibitor (1 mg/ml, sufficient to inhibit
3.2 mg of trypsin per ml) was added to both enzymes before
addition of each of the labeled and unlabeled substrates. In some
studies an extract from the spleen prepared similarly to the
brain extract was tested for enzymatic activity with both un-
labeled substrates. In all cases the samples were boiled for 5 min
to inactivate the enzymes before fractionation in the various
physicochemical systems to test for enzymatic conversion.
Radioimmunoassay. The gastrin and CCK peptides were
measured by radioimmunoassay according to published
methods (12-14). 125I-Gastrin-17 (porcine heptadecapeptide
gastrin was a gift from R. A. Gregory through the courtesy of
Morton Grossman, Wadsworth, VA) was used as tracer for both
assay systems. The guinea pig antiserum used for the gastrin
assay does not crossreact with CCK or CCK-8 (13). The anti-
serum obtained at the current bleedings of rabbit B crossreacts
identically with CCK and CCK-8 and somewhat more strongly
with gastrin-17. The crossreactivity with gastrin-17 does permit
use of 125I-gastrin-17 as a tracer but presents no problem since
pure CCK substrate is used in the CCK assays. Starch gel and
Sephadex eluates were assayed as described (12, 13).
RESULTS
125I-pCCK, in common with many peptide hormones such as
insulin, corticotropin, and parathyroid hormone, remains at the
site of application when applied to paper for chromatoelec-
trophoresis while the serum proteins, iodide, and other more
acidic peptides such as gastrin, CCK-8, and fragments such as
the iodotyrosines migrate anodally (12). Therefore, in this
system it is difficult to distinguish total proteolytic degradation
from specific cleavage to a fragment of CCK such as CCK-8.
However, paper chromatoelectrophoresis does serve as a rapid
screening test for degradative activity. Shown in Fig. 1 are in-
tact 125I-pCCK-33 before and after incubation at 25°C for 60
min with a fraction containing active enzyme. After Sephadex
G-50 and G-75 gel filtration of the brain extracts, only the void
volume region contained active fractions; i.e., those able to
fragment the 125I-CCK-33.
The void volulme eluate was incubated under the same con-
ditions also with '25I-gastrin-34, gastrin-34 (0.5 Mg/ml), and
pCCK-33 (0.5 Mg/ml) each in 0.25 M phosphate buffer (pH 7.5)
Serum AnodeOrigin proteins
FIG. 1. Paper chromatoelectrophoresis of 125I-CCK before
(Upper) and after (Lower) treatment with active fraction (void vol-
ume eluate after Sephadex G-50 gel filtration) of extract of pig cere-
bral cortex. Intact 125I-CCK remains at the site of application;
the 125I-labeled fragments migrate with the serum proteins.
fortified with 1 mg of human serum albumin per ml. The brain
enzyme was used at a concentration of 40 Ml of active fraction
per ml of incubation mixture. The same four substrates in the
same buffer were also incubated with 1 mg of trypsin per ml.
The starch gel electrophoretic patterns of the four substrates
before and after treatment with the two enzyme preparations
is shown in Fig. 2. Trypsin converted labeled and unlabeled
gastrin-34 to a peptide having the starch gel electrophoretic
behavior of gastrin-17 (Fig. 2 right, bottom). It also converted
labeled and unlabeled CCK-33 to a peptide resembling CCK-8(Fig. 2 left, bottom). However, the Sephadex G-50 void volume
eluate of the brain extract, which converted CCK-33 to smaller
immunoreactive peptides resembling CCK-12 and CCK-8 (Fig.
2 left, middle), did not alter gastrin-34 (Fig. 2 right, middle).
Other experiments over a range of enzyme concentrations(40-800 Ml of void volume eluate per ml) and substrate con-
centrations (0.2-5.0 ,g of CCK per ml) confirm the ability of
the brain enzyme to convert CCK to smaller immunoreactive
fragments and its failure to convert gastrin-34 to gastrin-17.
Thus, the substrate specificity for the brain enzyme does not
resemble trypsin. Furthermore, lima beam trypsin inhibitor
does not inhibit the brain enzyme at concentrations sufficient
to inhibit completely 1 mg of trypsin per ml of incubation
mixture. The brain enzyme also differs from trypsin in its
temperature sensitivity. Trypsin remained fully active in
converting CCK-33 to the smaller fragments when maintained
for 1 hr at temperatures up to 550C while the brain enzyme was
inactive when incubated with substrate for 1 hr at 450C.
The proteolytic activity of both the brain enzyme and trypsin
was maintained over the pH range from 6.5 to 9. As yet no at-
tempt has been made to determine pH optimum for activity
of the brain enzyme; it is inactive at pH 6 and below.
The brain enzyme differs significantly from trypsin not only
in substrate specificity and temperature sensitivity, but also in
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FIG. 2. Starch gel electrophoresis of 1251-labeled and unlabeled CCK and of 125I-labeled and unlabeled gastrin-34 before (Top) and after
treatment with brain converting enzyme (Middle) or with trypsin (Bottom). Trypsin converts labeled and unlabeled CCK to fragments with
starch gel electrophoretic mobility resembling CCK-8 and labeled and unlabeled gastrin-34 to fragments resembling gastrin-17. The brain con-
verting enzyme does not alter gastrin-34 but converts CCK to fragments with starch gel electrophoretic mobility resembling CCK-12 and CCK-8.
0, origin.
molecular size. Thus, the brain enzyme activity is found in the
void volume eluates on Sephadex G-75 fractionation while
trypsin appears in eluates at about 34% of the volume between
the void volume and the radioiodide peak. The void volume
fraction was centrifuged at 190,000 X g for 2 hr. The pellet was
resuspended in the original volume of saline. The enzyme ac-
tivity of the supernatant equalled that of the resuspended pellet.
Portions of both fractions were then subjected to density gra-
dient ultracentrifugation and their sedimentation pattern was
compared with that of 125I-albumin, 125I-gamma globulin, and
trypsin. Consistent with its known molecular size, the tryptic
proteolytic activity is recovered above albumin in the ultra-
centrifuge tube while the brain enzyme activity both of the
supernatant and of the resuspended pellet is found below
gamma globulin.
The species specificity of the brain enzyme was also inves-
tigated. The potency of canine cerebral cortex extracts in
converting pCCK to the smaller peptide did not differ signifi-
cantly from the potency of the porcine cerebral cortex ex-
tracts.
An enzyme similar to the brain enzyme could not be found
in the spleen. Splenic extracts prepared similarly to the brain
extracts completely destroyed the immunoreactivity of both
CCK-33 and gastrin-34, suggesting the presence of nonspecific
proteolytic enzymes. The void volume eluates of Sephadex G-75
filtration of the spleen extracts, prepared similarly with the
brain extracts, did not alter CCK-33.
DISCUSSION
Steiner and associates (9) have hypothesized that trypsin-like
and carboxypeptidase B-like proteinases have important roles
in the conversion of proinsulin into insulin as well as in the in-
tracellular processing of a variety of other precursor forms and
were able to demonstrate the existence of similar enzymatic
activities in the Islets of Langerhans. However, they were un-
able to implicate those enzymes directly in the endogenous
conversion process. MacGregor et al. (10) and later Habener
et al. (11) have demonstrated that subcellular fractions of bo-
vine parathyroid tissue contain enzymatic activity capable of
specifically converting the prohormone to intact parathyroid
hormone. None of these groups has presented evidence indi-
cating whether the converting enzyme studied was active in
converting two or more prohormones to smaller forms.
The present study was undertaken because of the demon-
stration that the cerebral cortical tissues from several mam-
malian species contain CCK peptides in amounts comparable
to those found in the gastrointestinal mucosa and that the
fraction of the immunoreactivity in components smaller than
CCK-33 is greater in the brain than in the gut (15). These ob-
servations suggested to us that brain extracts might contain an
enzyme of high potency for the specific conversion of CCK-33
to the smaller hormonal forms. The question answered by these
studies is that the brain enzyme, which is capable of cleaving
CCK-33 at the Arg-Ile bond to yield CCK-12 and at the Arg-
Asp bond to yield CCK-8, is more specific than simply tryp-
tic-like since, unlike trypsin, it fails to cleave big gastrin at the
Lys-Lys-Glu bonds. Furthermore, this enzyme can also be
distinguished from trypsin not only in terms of substrate spec-
ificity, but also in terms of molecular size, temperature stability,
and behavior in the presence of trypsin inhibitor.
Although the brain enzyme appears to manifest hormone
specificity, it does seem to effect cleavage at two different sites,
as shown by its ability to generate both CCK-12 and CCK-8.
This raises the possibility that there are two different but closely
related enzymes between which we have been unable to dis-
tinguish because our purification methods are as yet relatively
crude. There is no evidence that the enzyme is species specific
in that both canine and porcine cortical extracts appear to be
equally effective in cleaving porcine CCK-33. Thus, there is
Medical Sciences: Straus et al. 5713
5714 Medical Sciences: Straus et al.
no reason to believe that the failure of porcine brain enzyme
to convert human gastrin-34 to gastrin-17 was due to species
specificity. The enzyme has some degree of organ specificity
in that a degradative enzyme of the same molecular size was
not detectable in splenic extracts, which contain nonspecific
proteases capable of completely degrading CCK.
In our studies we have had no problem solubilizing a major
fraction of the converting enzyme. The supernatant fraction,
after centrifugation for 2 hr at 190,000 X g, contained half the
activity and this activity was shown to be associated with a
molecule somewhat larger than gamma globulin. We have not
yet determined whether the packaging of converting enzyme
and the CCK hormonal substrate is different in the brain from
in glandular tissue or whether there is a converting enzyme in
gut that is as easily solubilized.
It is of interest to consider some possible comparisons between
the CCK-converting enzyme system described here and the
kidney renin-brain isorenin systems (see ref. 16 for review). The
converting enzymes of the renin-angiotensin and the CCK
systems do not have the dibasic peptide specificity characteristic
of many other prohormone-hormone systems. The brain and
kidney renins are similar in molecular size and certain other
physical chemical properties, including sufficient structural
identity so that antibodies against dog kidney renin also have
an inhibitory effect on brain isorenin activity. Furthermore,
both renins from one species are active on substrates from an-
other species. Nonetheless, the brain and kidney enzymes are
not identical in that rat brain isorenin has high affinity for dog
substrate whereas rat kidney renin does not. Thus, brain and
kidney renins are similar but not identical. Further investigation
is required to determine whether the enzyme in the gut that
converts CCK to the bioactive and immunoactive COOH-ter-
minal fragments resembles or is different from that found in
the brain.
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